Common Subtype of Small Renal Mass MR Imaging Characterisation: A Medical Center Experience in Taiwan
03 medical and health sciences
0302 clinical medicine
3. Good health
DOI:
10.1007/s40846-022-00684-w
Publication Date:
2022-02-03T02:02:36Z
AUTHORS (8)
ABSTRACT
Abstract
Purpose
Many studies have shown that multiparametric magnetic resonance imaging (MRI) may be helpful for differentiating malignant renal cell carcinomas (RCCs) from benign lesions. However, the key imaging characteristics that differ between malignant and benign tumors still require further discussion.
Methods
We analyzed 60 adult patients diagnosed with 72 small renal masses (SRMs) who received preoperative MRI from 2014 to 2019 at a hospital in Taiwan. The MRI features included conventional MRI parameters, diffusion-weighted imaging (DWI) data, and dynamic contrast-enhanced (DCE) patterns, which were documented and compared among the four common subtypes: clear cell RCC (ccRCC), papillary RCC (pRCC), angiomyolipoma (AML) and other types of RCC. The apparent diffusion coefficient (ADC) values of high- and low-grade RCCs were also analyzed.
Results
The results show that ccRCC had higher T2-weighted signal intensity than the other three subgroups, a higher arterial wash-in index (AWI) and ADC value than AML and pRCC, and manifested a plateau (n = 9, 25%) or washout (n = 27, 75%) enhancement pattern. AMLs exhibited more intravoxel fat than the other three subtype groups, and half of the AMLs (6 in 12) contained bulk fat. pRCC demonstrated a more progressive (n = 3, 60%) enhancement pattern than the other three subgroups. The ADC value of high-grade RCCs was significantly lower than that of low-grade RCCs.
Conclusion
These findings may indicate that multiparametric MRI is useful in differentiating among four common pathological types of SRMs, and the ADC value may be helpful in evaluating the histological grade of malignancy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....